Newswire (Published: Friday, April 12, 2019, Received: Friday, April 12, 2019, 4:02:07 PM CDT)

Word Count: 469

2019 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Daily News -- Researchers detail new data in Drugs and Therapies - Brachytherapy. According to news originating from Beijing, People’s Republic of China, by NewsRx correspondents, research stated, “The aim of this study was to evaluate the efficacy and safety of interstitial permanent low-dose-rate ultrasound-guided I-125 seeds implantation of local head and neck recurrent tumors. Sixty-four consecutive patients, with 81 lesions in total, underwent permanent implantation of I-125 seeds under ultrasound guidance.”

Our news journalists obtained a quote from the research from Peking University, “Post-operative dosimetry was performed for all patients. Follow-up period ranged 103.5 months (median, 14 months). Among the 81 lesions, the totally response rate was 80.2%, and 22 (27%) and 43 (53%) lesions showed complete and partial remission. The 1-, 3-, and 5-year tumor control rates were 75.2%, 73.0%, and 69.1%, respectively. The results for cervical lymph node recurrence were better than those for recurrence or residual disease of primary head and neck neoplasms, with 5-year local control rates of 72.7% and 39.9%, respectively. D-90 was an independent prognostic factor of the tumor control, and lesion recurrence location and time to tumor progression were prognostic factors of survival. As of the date of follow-up, 22 of 64 patients were still alive. The 1-, 3-, and 5-year overall survival rates were 57.4%, 31%, and 26.6%, respectively, with a median survival of 20 months. Grade 4 skin ulceration was seen in two patients; grade 1 or 2 skin reactions were seen in 11 patients (17%) who had received external beam radiotherapy before. Other severe complications were absent.”

According to the news editors, the research concluded: “Interstitial permanent implantation of I-125 seeds under ultrasound guidance is feasible, efficacious, and safe for refractory head and neck metastasis or recurrence.”

For more information on this research see: Five-year Outcome of Ultrasound-guided Interstitial Permanent I-125 Seeds Implantation for Local Head and Neck Recurrent Tumors: a Single Center Retrospective Study. Journal of Contemporary Brachytherapy, 2019;11(1):28-34. Journal of Contemporary Brachytherapy can be contacted at: Termedia Publishing House Ltd, Kleeberga St 2, Poznan, 61-615, Poland.

The news correspondents report that additional information may be obtained from J.J. Wang, Peking University, Dept. of Radiation and Oncology, Third Hospital, Beijing, People’s Republic of China. Additional authors for this research include P. Jiang, W.Q. Ran, Y.L. Jiang, S.Q. Tian and H.T. Sun.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.5114/jcb.2019.83336. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Peking University

Industries

Healthcare
      Medical Devices
            Medical Treatment Devices
                  Radiosurgery Devices
Information and Media
      Publishing
Manufacturing
      Medical Device Manufacturing
            Medical Devices
                  Medical Treatment Devices
                        Radiosurgery Devices

Places

Eastern Asia
Eastern Europe
People's Republic of China
Poland
Asia
Europe
Beijing

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies